Critical reappraisal of remdesivir investigational trials in COVID-19

During disease outbreaks, the pharmaceutical industry generally puts a lot of effort into promoting clinical trials studying their new drugs. We review evidence of the ten most recent reports on remdesivir. We conclude that it is far too premature to identify remdesivir as a curative or life-saving...

Descripción completa

Detalles Bibliográficos
Autores principales: Brouqui, P., Giraud-Gatineau, A., Raoult, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Mini-Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567956/
https://www.ncbi.nlm.nih.gov/pubmed/33088576
http://dx.doi.org/10.1016/j.nmni.2020.100745
Descripción
Sumario:During disease outbreaks, the pharmaceutical industry generally puts a lot of effort into promoting clinical trials studying their new drugs. We review evidence of the ten most recent reports on remdesivir. We conclude that it is far too premature to identify remdesivir as a curative or life-saving intervention during the COVID-19 pandemic.

Ejemplares similares